Enanta Pharmaceuticals (ENTA) 2026 Global Healthcare Conference summary

Strategic focus and pipeline evolution

• Core strengths are in drug discovery and development, with a pipeline of wholly owned assets, especially outside hepatitis.

• Expanded from liver virology to respiratory virology, notably RSV, and now into immunology and inflammation (I&I) leveraging internal expertise.

• I&I viewed as a growing opportunity, building on virology experience and staff with immunology backgrounds.

RSV clinical development highlights

• Zelicapavir, a replication inhibitor, has shown strong safety and antiviral activity in over 700 patients, with focus shifting to high-risk populations.

• LOTUS pediatric study in Thailand targets children aged 4 weeks to 3 years, using a newly developed observer-reported outcome tool as the primary endpoint.

• Prior studies showed about 1.2 log reduction in viral load and meaningful symptom improvement, especially when treated early.

• RESOLVE phase II-B/III study in high-risk elderly (75+ or with comorbidities) aims to confirm symptom resolution and reduced hospitalization, with a single registration study design.

• FDA guidance led to inclusion of both vaccinated and unvaccinated patients, with interim analysis to calibrate phase III endpoints.

I&I pipeline and target selection

• Target selection prioritizes clinical validation, market size, and competitive potential, with a focus on areas where small molecules can offer advantages over biologics.

• KIT inhibitor in phase I aims for oral dosing and dose-dependent serum tryptase reduction, with potential for better patient convenience and safety profile compared to antibodies.

• Phase I data will inform dosing strategies to balance efficacy and minimize on-target side effects like changes in skin/hair color and neutrophil counts.

• STAT6 inhibitor program targets continuous, potent, and selective inhibition, aiming for DUPIXENT-like efficacy in atopic dermatitis and asthma models.

• MRGPRX2 antagonist program explores novel mast cell-driven disease mechanisms, including potential applications in migraine, with candidate selection progressing rapidly.